1. Lower expression of miR-218 in human breast cancer is associated with lymph node metastases, higher grades, and poorer prognosis
    Fereshteh Ahmadinejad et al, 2017, Tumour Biol. CrossRef
  2. MicroRNA-19b inhibits proliferation of gastric cancer cells by targeting B-cell CLL/lymphoma 3
    Huan Wang et al, 2016 CrossRef
  3. BMI1: A Biomarker of Hematologic Malignancies.
    Anagh A Sahasrabuddhe, 2016, Biomark Cancer CrossRef
  4. Prognostic significance of low microRNA-218 expression in patients with different types of cancer
    Fujiao Duan et al, 2016, Medicine CrossRef
  5. ATPase inhibitory factor 1 is a potential prognostic marker for the migration and invasion of glioma
    JIANHENG WU et al, 2015 CrossRef
  6. miR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer
    WENQI MA et al, 2016 CrossRef
  7. microRNAs involved in Parkinson's disease: A systematic review
    Franciele Cascaes Da Silva et al, 2016 CrossRef
  8. TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma.
    Yuqi Huang et al, 2014, Int J Mol Sci CrossRef
  9. miR-218 expression in osteosarcoma tissues and its effect on cell growth in osteosarcoma cells
    Hong-Tai Wang et al, 2014, Asian Pacific Journal of Tropical Medicine CrossRef
  10. MiR-218-targeting-Bmi-1 mediates the suppressive effect of 1,6,7-trihydroxyxanthone on liver cancer cells
    Wei-Ming Fu et al, 2015, Apoptosis CrossRef
  11. Inhibition effect of miR-577 on hepatocellular carcinoma cell growth via targeting β-catenin
    Li-Yan Wang et al, 2015, Asian Pacific Journal of Tropical Medicine CrossRef
  12. RETRACTED ARTICLE: Up-regulation of miR-130b expression level and down-regulation of miR-218 serve as potential biomarker in the early detection of human osteosarcoma
    Afshin Taheriazam et al, 2015, Diagn Pathol CrossRef
  13. Expression of microRNA-218 and its Clinicopathological and Prognostic Significance in Human Glioma Cases
    Mao-Wei Cheng et al, 2015, Asian Pacific Journal of Cancer Prevention CrossRef
  14. microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma
    Lei Zhang et al, 2016, FEBS Open Bio CrossRef
  15. Knockdown of terminal differentiation induced ncRNA (TINCR) suppresses proliferation and invasion in hepatocellular carcinoma by targeting the miR‐218‐5p/DEAD‐box helicase 5 (DDX5) axis
    Huibo Zhao et al, 2020, J Cell Physiol CrossRef
  16. Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis
    Chao Li et al, 2017, Oncotarget CrossRef
  17. Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma
    Zhikui Liu et al, 2016, Oncotarget CrossRef
  18. Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis
    Yue Zhang et al, 2017, Oncotarget CrossRef
  19. miR‑218 inhibits acute promyelocytic leukemia cell growth by targeting BMI‑1
    Yan Wang et al, 2017, Oncol Lett CrossRef
  20. miRNA-218 regulates the proliferation and apoptosis of cervical cancer cells via targeting Gli3.
    Jing Zhang et al, 0 CrossRef
  21. MicroRNA-1271 functions as a metastasis and epithelial-mesenchymal transition inhibitor in human HCC by targeting the PTP4A1/c-Src axis
    Chao Li et al, 2017, Int J Oncol CrossRef
  22. Targeted Delivery of miR-218 via Decorated Hyperbranched Polyamidoamine for Liver Cancer Regression
    Asmaa M. Elfiky et al, 2021, International Journal of Pharmaceutics CrossRef
  23. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma
    Ru Wang et al, 2022, Technol Cancer Res Treat CrossRef
  24. miR-498 Targets UBE2T to Inhibit the Proliferation of Malignant Melanoma Cells
    Wen Cao et al, 2022, Technol Cancer Res Treat CrossRef
  25. The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies
    Jie Xu et al, 2022, IJMS CrossRef